Professional investor and overall good guy.
By reading Mako Research reports, you agree to use the information at your own risk. In no event should Mako Research or any affiliated party be liable for any direct or indirect trading losses caused by information contained in the research reports. Research reports are not investment advice or a recommendation or solicitation to transact any securities. Mako Research is not a registered investment advisor. You agree to do your own research and due diligence before making any investment decision with respect to securities covered herein. You should assume that Mako Research stands to profit in the event the issuer’s stock declines. Research reports may contain opinions, which are based upon generally available public information, field research, inferences and deductions through due diligence and analytical processes. All information is believed to be accurate and reliable, and has been obtained from public sources. Mako Research makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information. All expressions of opinion are subject to change without notice, and Mako Research is not obligated to update or supplement any reports or any of the information, analysis and opinion contained in them. You should assume that Mako Research has and/or will submit findings with the Securities Exchange Commission, and other entities that may find the information useful.
Team StockMatusow.com research and writers are:
Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com.
Scott is an independent investor/writer/trader and team leader of StockMatusow.com.
He has have about 17 years of stock market experience which include trading, investing, and managing his family’s trust as well as his personal account.
Scott has had the most success in trading/investing in smaller cap growth companies. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. Using these acquired allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis.
Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. Additionally, Dan is a Scientist and inventor. He has 7 years of experience investing and trading biotechnology focused equities with a specialty in identifying under-appreciated value in small caps. Dan utilizes his experience reading and reviewing scientific literature to evaluate prospects for success. His work with diagnostics development give him a strong background in immunology which is leveraged in evaluating immunoncology focused approaches. As well Dan has 5 years trading futures, specializing in E-minis and Treasury products. He utilizes a combination of technical analysis, deep scientific research, and macro views to generate alpha for the team.
Places you can follow Scott are:
Places to follow Dan are:
A hobby investor turned full time investor with over 20 years of experience in trading. My trading experience consists of trading in markets such as commodity, options, energy, biotechs, and pharmaceuticals sectors. As an investor I use a wide range of tools such as utilizing basic financial trends, chart trends, short activities and a mix of due diligence in any stock I review or analyze.
I'm currently based in sunny California in which I enjoy being a successful full time investor and trader in various sectors.
H.B.Sc. from the University of Toronto specializing in Biology and Life Sciences, current Doctor of Optometry candidate studying at the University of Waterloo, started my own business in 2014 in the retail healthcare sector, and currently manage my own portfolio of investments while studying.
Got into investing because I love the research element of finding a special opportunity, and having real time feedback on whether the logic used was right. I have no formal education in this field, everything I know is from dozens of books, and hundreds of articles, interviews, and podcasts that I've read and listened to in the past few years. I look for asymmetric opportunities that provide quick option like gains on investment to bolster returns while holding other assets for long term growth. I'm open to further opportunities in this field, feel free to get in touch.
Lastly, I am young and learning every day, and acknowledge the likelihood that my opinions and strategies will develop and change as I gain further knowledge and experience in this field. Thus, this is a disclaimer that I am not a certified, registered, or accredited financial planner and/or investor, and material provided by me is my own opinion and purely for informational/entertainment purposes.
Cheers and thanks for visiting,
Be healthy, wealthy, happy, and savvy
The Clinically Sound Investor is a pharmacist with a PharmD and a BA in psychology. He has worked across the spectrum from very small independent and hospital pharmacies to the some of the largest retail corporations and medical centers in the nation, as well as experience in specialty and mail order settings. Fascinated by watching the rise of Walmart and Apple after 2008, he now follows the advice "know thyself" and puts expertise of understaning scientific literature to research biotechnology stocks. His investments early on were driven by binary events such as FDA Advisory Committee meetings and PDUFA dates (approvals). Despite initial successes, there were too few of these events, so he expanded into predicting Phase II/III trial results. His writings should not be considered financial advice or the basis for investment decisions. While his interpretations of clinical trial results--which may be overlooked or even thoroughly misunderstood by Wall Street--could be helpful, they're only as good as the original reports they come from. Although written by scientists and doctors, there will always be a slant from the sponsoring company, or worse (like, say, missing data...).
We look for potentially undervalued stocks in biotech, technology, and commodities sectors.
We perform research, and give investment opinions and ideas to buy-side firms from time to time.
We do not discuss unpublished reports, or provide any advanced warning of future reports to others.
We are not advisors.
Having always been a learning machine, I speak five languages, have worked as a sales agent, project manager, translator, computer consultant, software engineer, built a house with my own hands, published books and essays on literature, philosophy and art, have written for magazines of various kinds in different countries.
After retiring early in 2004, little by little, I have become a fund manager for some friends and myself, following the principles of value investing laid out by Benjamin Graham, Phil Fisher, Charlie Munger and Warren Buffett. You can read about my thoughts on a suitable portfolio structure for early retirees here.
My articles should not be considered to be any kind of investment advice. What suits me well is not necessarily good for others, as successful investing is somewhat like a marriage: If only one is perfect, the marriage won’t work. So please do your own research and remember Benjamin Graham's advice: “The investor’s chief problem — and even his worst enemy — is likely to be himself.”
I run a very concentrated portfolio with 10-15 positions and invest for the long term. As of 12/2016, my largest position is Theravance Biopharma (TBPH), a company I had intensively and extensively researched long before any sell-side analyst noticed the stock. You can find my early work on TBPH on this site and my comprehensive in-depth research reports on all important pipeline assets here. I correctly predicted the evolution of the new GOLD guidelines for COPD, the sales trajectory of Vibativ and GSK's new Ellipta product range. My reports have been far ahead (in terms of depth, scope and reliability) of all sell-side work on TBPH. That said, I obviously make mistakes as well, although I've yet to make one that costs me serious money.
Other long-time favorites of mine are DaVita (DVA), IBM and a few European small caps which I have also partly covered on Seeking Alpha, e.g. Admiral (AMIGF), Fuchs Petrolub (FUPEF).
I am an individual investor who has been actively involved in the healthcare and biotechnology space for over 15 years. I hold a PhD in the biomedical sciences and have worked in both large pharmaceutical and small biotech companies. I make investments based on the fundamentals of a company and if I believe they have a superior technology or products compared to the competition. I'm an investor who believes patience pays off.
Editor for The Biotech Forum (www.biotechforumsa.com), the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade. For Free weekly investment reports on small, attractive biotech stocks just register at www.bretjenseninvests.com
Independent writer/trader/investor that tends to write more for informational purposes than to advance a particular trading position. Please click to follow me if you like my work. There’s an option to follow me at the top of my articles. Best functionality of site is on desktop.
I’M NOT A FINANCIAL ADVISOR OR SCIENTIST & ONLY GIVE MY OPINIONS. SEEK EXPERT ADVICE ELSEWHERE. ;) Investment Philosophy: Understand why you are getting in.
My positions, long or short can change dramatically as new information comes to my attention. All stocks are risky, but, don't follow me into a penny stock without realizing they are HIGHLY risky and you can lose ALL of your investment.
No payment in any form is accepted for my writing by any company or other party. I only receive that which comes from writing on Seeking Alpha.
Education is an undergraduate degree in Business Administration and Management. Masters' in Organizational Management.
Be kinder than necessary, for everyone you meet is fighting some kind of battle. ;)